Aptinyx stock falls 67% after phase 2 trial fails to meet primary endpoint

Shares of Aptinyx Inc. fell 67% in premarket trade Wednesday after the biotech company announced that the phase 2 study of its treatment for painful diabetic peripheral neuropathy did not meet its primary endpoint. The therapy, NYX-2925, did not show a significant difference in patients' daily pain scores compared to placebo, Aptinyx said. The company said it is also conducting an exploratory phase 2 study of NYX-2925 in patients with fibromyalgia, and said a full analysis of the data should be available in the first half of 2019. Shares of Aptinyx have gained 7.8% in the year through Tuesday, while the S&P 500 has gained 4.1%. The iShares Nasdaq Biotechnology ETF has gained 13.3%.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.